Evidence map›Paper›PMID 41193537›Full record

Observational studyScientific reports2025

Diagnostic utility of high-mobility group box 1 for acute exacerbations of idiopathic pulmonary fibrosis.

Naoki Hamada, Shoji Tokunaga, Toyoshi Yanagihara, Kazuya Tsubouchi, Katsuyuki Ichiki, Shohei Takata, Hiroshi Ishii, Yasuhiko Kitasato, Masaki Okamoto, Kazuhiro Yatera and 14 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Naoki HamadaDepartment of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. nhamada@fukuoka-u.ac.jp.
Shoji TokunagaClinical Research Support Center, Ehime University Hospital, Toon, Japan.
Toyoshi YanagiharaDepartment of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Kazuya TsubouchiDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Katsuyuki IchikiKirigaoka Tsuda Hospital, Kitakyushu, Japan.
Shohei TakataDepartment of Respiratory Diseases, National Hospital Organization Fukuokahigashi Medical Center, Fukuoka, Japan.
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan.
Yasuhiko KitasatoDepartment of Respiratory Medicine, Japan Community Healthcare Organization Kurume General Hospital, Kurume, Japan.
Masaki OkamotoDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Kazuhiro YateraDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Masayuki KawasakiDepartment of Respiratory Diseases, National Hospital Organization Omuta National Hospital, Omuta, Japan.
Makoto YoshidaDepartment of Respiratory Diseases, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.
Takashige MaeyamaDepartment of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, Japan.
Masaki FujitaDepartment of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Ayano MashimotoDepartment of Respiratory Medicine, Japan Community Healthcare Organisation Kyushu Hospital, Kitakyushu, Japan.
Kazuto FuruyamaDepartment of Respiratory Medicine, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Ryo ToriiDepartment of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Kunihiro SuzukiDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
Yuichi MizutaDepartment of Respiratory Medicine, St Mary's Hospital, Kurume, Japan.
Kazunori TobinoDivision of Respiratory Medicine, Aso Iizuka Hospital, Iizuka, Japan.
Eiji HaradaDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Hidetake YabuuchiDepartment of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Isamu OkamotoDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoichi NakanishiKitakyushu City Hospital Organization, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no established biomarkers for acute exacerbations in idiopathic pulmonary fibrosis (AE-IPF). The bronchoalveolar lavage fluid of patients with IPF notably has elevations in high-mobility group box 1 protein (HMGB1), a nuclear non-histone chromosomal protein that functions as an alarmin that perpetuates the inflammatory process. This study investigated the potential of serum HMGB1 levels as a diagnostic marker for AE-IPF. This prospective, multicenter, observational cohort study included 779 HMGB1 readings from 269 Japanese patients with IPF. Diagnostic performance was assessed using four different methods of recording serial HMGB1 measurements rather than relying on a simple comparison between stable IPF and AE-IPF. Additionally, KL-6 was measured in cases of stable IPF and AE-IPF. A comparative analysis for the usefulness of HMGB1 and KL-6 as biomarkers for AE-IPF was performed. The cohort accounted for 505.6 person-years, with a mean follow-up duration of 1.88 years. A total of 46 cases with AE were recorded with their corresponding HMGB1 levels. All four diagnostic methods examined had high diagnostic accuracy (area under the curve > 0.75). HMGB1 had significantly better diagnostic performance than KL-6. HMGB1 demonstrated high diagnostic utility in AE-IPF, which can be used to facilitate earlier diagnosis and treatment.

Indexed as

HMGB1 ProteinIdiopathic Pulmonary FibrosisAgedBiomarkersBronchoalveolar Lavage FluidFemaleHumansMaleMiddle AgedMucin-1Prospective StudiesBiomarkersHMGB1 ProteinHMGB1 protein, humanMUC1 protein, humanMucin-1

Identifiers

PMID41193537
PMCPMC12589390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.